PE20181329A1 - Metodos y composiciones para el tratamiento del sindrome de hunter - Google Patents

Metodos y composiciones para el tratamiento del sindrome de hunter

Info

Publication number
PE20181329A1
PE20181329A1 PE2018001230A PE2018001230A PE20181329A1 PE 20181329 A1 PE20181329 A1 PE 20181329A1 PE 2018001230 A PE2018001230 A PE 2018001230A PE 2018001230 A PE2018001230 A PE 2018001230A PE 20181329 A1 PE20181329 A1 PE 20181329A1
Authority
PE
Peru
Prior art keywords
methods
compositions
hunter
syndrome
treatment
Prior art date
Application number
PE2018001230A
Other languages
English (en)
Inventor
Torayuki Okuyama
Thong-Gyu Jin
Han-Yeul Byun
Jin-Wook Seo
Byoung-Ju Lee
Yong-Chul Kim
In-Young Jang
Kyuhyun Lee
Original Assignee
Green Cross Corp
Medigenebio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp, Medigenebio Corp filed Critical Green Cross Corp
Publication of PE20181329A1 publication Critical patent/PE20181329A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a composiciones y metodos para la administracion intracerebroventricular (ICV) de idursulfasa-beta (IDS-B), una proteina iduronato- 2-sulfatasa recombinante humana, para el tratamiento eficaz del Sindrome de Hunter. Tambien se refiere a metodos que reducen eficazmente los sintomas no solo en el cerebro y la medula espinal sino tambien en los tejidos perifericos que incluyen higado, bazo y rinon.
PE2018001230A 2015-12-30 2016-12-21 Metodos y composiciones para el tratamiento del sindrome de hunter PE20181329A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562272843P 2015-12-30 2015-12-30
US201662369970P 2016-08-02 2016-08-02

Publications (1)

Publication Number Publication Date
PE20181329A1 true PE20181329A1 (es) 2018-08-20

Family

ID=59224844

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001230A PE20181329A1 (es) 2015-12-30 2016-12-21 Metodos y composiciones para el tratamiento del sindrome de hunter

Country Status (19)

Country Link
US (1) US11052135B2 (es)
EP (1) EP3397270B1 (es)
JP (2) JP2019504053A (es)
KR (2) KR20180090387A (es)
CN (1) CN108430494A (es)
BR (1) BR112018013421A2 (es)
CL (1) CL2018001782A1 (es)
CO (1) CO2018007251A2 (es)
DK (1) DK3397270T3 (es)
EA (1) EA201891533A1 (es)
FI (1) FI3397270T3 (es)
HK (1) HK1258054A1 (es)
MX (1) MX2018008029A (es)
MY (1) MY193846A (es)
PE (1) PE20181329A1 (es)
PH (1) PH12018550102A1 (es)
SG (1) SG11201805598WA (es)
UA (1) UA123704C2 (es)
WO (1) WO2017116066A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
CN112236164A (zh) * 2018-05-30 2021-01-15 株式会社医用基因生物 用于通过侧脑室施用治疗亨特综合征的方法和组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
IL291554B2 (en) * 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
PL2588130T3 (pl) 2010-06-25 2017-09-29 Shire Human Genetic Therapies, Inc. Dostarczanie środków terapeutycznych do OUN
JP6045492B2 (ja) * 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
BR112013020195B1 (pt) 2011-02-11 2020-01-07 Swedish Orphan Biovitrum Ab (Publ) Composição farmacêutica livre de citrato compreendendo anakinra e uso de anakinra
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
EA201792099A1 (ru) 2011-12-23 2018-05-31 Шир Хьюман Дженетик Терапис, Инк. Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы
US9603908B2 (en) * 2012-03-30 2017-03-28 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate-2-sulfatase

Also Published As

Publication number Publication date
CN108430494A (zh) 2018-08-21
US11052135B2 (en) 2021-07-06
EP3397270A4 (en) 2019-09-18
MX2018008029A (es) 2018-08-23
KR102272399B1 (ko) 2021-07-05
KR20180090387A (ko) 2018-08-10
FI3397270T3 (fi) 2024-05-10
BR112018013421A2 (pt) 2018-12-18
UA123704C2 (uk) 2021-05-19
MY193846A (en) 2022-10-28
EA201891533A1 (ru) 2018-12-28
CL2018001782A1 (es) 2018-11-09
EP3397270B1 (en) 2024-04-17
SG11201805598WA (en) 2018-07-30
EP3397270A1 (en) 2018-11-07
JP6987924B2 (ja) 2022-01-05
KR20200099621A (ko) 2020-08-24
JP2019504053A (ja) 2019-02-14
HK1258054A1 (zh) 2019-11-01
JP2020147578A (ja) 2020-09-17
CO2018007251A2 (es) 2018-07-19
PH12018550102A1 (en) 2019-02-11
US20200268857A1 (en) 2020-08-27
DK3397270T3 (da) 2024-05-06
WO2017116066A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
EA201792501A1 (ru) Вакцины для лечения и профилактики рака
MX2015003229A (es) Composiciones que comprenden mezclas de alcanos semifluorados.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
WO2015103438A3 (en) Oncolytic virus adjunct therapy with agents that increase virus infectivity
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
AR088044A1 (es) Proteinas de fusion para tratar trastornos metabolicos
EA201591839A1 (ru) Терапевтические пептиды
BR112016029906A2 (pt) compostos excipientes redutores de viscosidade para formulações proteicas
EA201891364A1 (ru) Производные инозитола для применения в патологической кристаллизации
BR112016006564A2 (pt) proteínas de ligação desmogleína 2 (dsg2) e usos das mesmas
EA201792304A1 (ru) Комбинированная терапия для лечения рака
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
EA201591925A1 (ru) Терапевтические композиции и их применение
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
EA201792256A1 (ru) Соли и пролекарства 1-метил-d-триптофана
PE20181329A1 (es) Metodos y composiciones para el tratamiento del sindrome de hunter
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease